For analysts eagerly anticipating developments with Antegren, Elan Corp. plc's multiple sclerosis drug, the news last week that Prialt, its first pain product, gained a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use was a pleasant sideshow. (BioWorld International) Read More
